Check out your Company Bowl for anonymous work chats.
Evonik invests US$220 million in partnership with the U.S. Government to build new lipid production facility for mRNA-based therapies in the U.S. The new plant at Evonik’s Tippecanoe site in Lafayette, Indiana, will broadly position the Group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines and strengthen its leading role as a strategic partner for innovative pharmaceutical companies worldwide.
DIVERSITY AT EVONIK Diversity creates growth, innovation and customer proximity We are convinced of the power of diversity. At Evonik, we promote an open performance culture in which all employees have equal opportunities regardless of race, ethnicity, age, religion, gender, sexual orientation or disability. We focus on transparency, networking, and support for all of our employees and, based on this, we offer a wide range of offers and measures in order to anchor diversity firmly in our corporate culture. Check out our new diversity page!
